General Info

06 November 2009 SUCCESSFUL BONE MARROW REGENERATION IN CANCER PATIENTS USING CORD BLOOD EXPANDED BY PROPRIETARY STEM CELLS 25 August 2009 ANGIOBLAST CLOSES $10M EQUITY-BASED FINANCINGANGIOBLAST CLOSES $10M EQUITY-BASED FINANCING Angioblast Systems, Inc ( Angioblast or the Company ) is a privately held biotechnology company formed in 2001. The Company is committed to becoming a world leader in the development and commercialization of novel therapeutic products for the treatment of cardiovascular diseases ( CVD ) and vascular disorders. Angioblast intends to achieve this goal through the advancement of its three lead and groundbreaking product candidates that have each been proven to be effective in animal models of human CVD: products delivered in drug-eluting stents for coronary and peripheral artery disease, consisting of RNA silencing technology, the lead candidate targeting the blood vessel and clotting regulator plasminogen activator inhibitor type I ( PAI-1 ) Each of the Company's lead products and underlying proprietary technology platforms ( which are covered by an extensive patent portfolio ) operates primarily by regulating blood vessel growth. Therefore, these lead product candidates and the related technologies are applicable to a broad range of diseases where new blood vessel growth may be useful, including congestive heart failure, myocardial infarction ( heart attack ), peripheral arterial disease and skin ulcers. The Company's most advanced product is the MPC therapy, which has achieved outstanding results in extensive pre-clinical development in animal models of several cardiovascular diseases, including studies focused on the regeneration and repair of heart muscle and growth of new blood vessels following a heart attack injury. This product represents what Angioblast believes is the world's leading adult stem cell technology, a groundbreaking advancement in stem cell-based clinical treatment, and which is currently being evaluated in a human clinical trials for treatment of heart damage following a heart attack.